Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 2/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | FABP2 | P12104 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terofenamate SCHEMBL49245 | 0.95 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL23803169 | 0.94 | METTL3 (0.72) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL7705424 | 0.94 | METTL3 (0.78) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL9856559 | 0.94 | METTL3 (0.81) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL5089764 | 0.94 | METTL3 (0.81) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL26088 | 0.94 | METTL3 (0.84) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL29483481 | 0.94 | METTL3 (0.84) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL7634355 | 0.93 | METTL3 (0.76) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL3805644 | 0.93 | METTL3 (0.79) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL4742611 | 0.93 | METTL3 (0.79) | METTL3PTGS2MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| EP-4319752-A1 | CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER | Repare Therapeutics Inc. (CA) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022213204-A9 | CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER | REPARE THERAPEUTICS INC. (CA) | 2023-11-16 | — | — | WO | disclosed |
| US-20230158022-A1 | METHODS OF USING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2023-05-25 | — | — | US | disclosed |
| US-20230151014-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230122909-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2023-04-20 | — | — | US | disclosed |
| CN-115916783-A | Compounds, pharmaceutical compositions and methods of making compounds and methods of use thereof | 修复治疗公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115811976-A | Methods of using MYT1 inhibitors | 修复治疗公司 | 2023-03-17 | — | — | CN | disclosed |
| EP-4126879-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | Repare Therapeutics Inc. (CA) | 2023-02-08 | — | — | EP | disclosed |
| EP-4125907-A1 | METHODS OF USING MYT1 INHIBITORS | Repare Therapeutics Inc. (CA) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022213204-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-10-13 | — | — | WO | disclosed |
| WO-2021195782-A1 | METHODS OF USING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021195781-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2021-10-07 | — | — | WO | disclosed |
| US-20130101684-A1 | Compounds, Compositions, And Methods For Reducing Or Eliminating Bitter Taste | CHROMOCELL CORPORATION (US) | 2013-04-25 | — | — | US | disclosed |
| EP-2558067-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE | Chromocell Corporation (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130707-A9 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE | CHROMOCELL CORPORATION (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011130707-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE | CHROMOCELL CORPORATION (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122909-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | PLK1, CSNK1A1, CSNK1G1 | METTL3 2881/4885PTGS2 4271/4885MEN1 651/4885 |
| US-20130101684-A1 | Compounds, Compositions, And Methods For Reducing Or Eliminating Bitter Taste | TAS2R5, TAS2R20, TAS2R10 | METTL3 1325/4885PTGS2 1936/4885MEN1 347/4885 |
| US-20230158022-A1 | METHODS OF USING MYT1 INHIBITORS | MYT1, MNAT1, MYLK3 | METTL3 1163/4885PTGS2 4708/4885MEN1 876/4885 |
| US-20230151014-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | PLK1, CSNK1A1, CSNK1G1 | METTL3 2881/4885PTGS2 4271/4885MEN1 651/4885 |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | WEE2, WEE1, KAT2A | METTL3 1112/4885PTGS2 3549/4885MEN1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.